Malignancy Clinical Trial
Official title:
Real-time Ultrasound-Guided Needle Biopsy in the Diagnosis of Malignant Cervical Lymphadenopathies
The objective of the present study was to compare ultrasound (US) characteristics and ultrasound-guided core-needle biopsy (US-CNB) with US-guided fine-needle aspiration (US-FNA) in the assessment of different malignant cervical lymphadenopathies. Patients with malignant cervical lymphadenopathie with either US-FNA or US-CNB over a 3-year period from 2007 July to 2010 Dec were retrospectively reviewed. There are two major study groups according to the treatment status of the patient's population, including patients who had pathology proofed previous cancer and with clinically cervical lymphadenopathies after treatment. The second group included patients with cervical lymphaenopathies but without previous diagnosis of malignancy and treatment. The results of cytology, or pathology and time of needle biopsy to final diagnosis were traced and recorded. Morphologic US parameters and vascular features were thoroughly evaluated and compared in different disease.
Introduction
In the absence of infection signs, lateral neck lymphadenopathies should be suspected as
metastatic carcinoma or lymphoma until proved otherwise. Previously, the most commonly used
sampling techniques in the head and neck are the open excisional biopsy and fine-needle
aspiration (FNA) cytology. Open biopsy and lymph node excision provides material suitable
for histological analysis but is invasive and may entail general anesthesia and hospital
admission. Besides, excisional and incisional biopsy of cervical metastases results in a 2-3
times increased incidence of local treatment failure when compared with FNA cytology.
High-resolution ultrasound is widely used imaging modality to evaluate the morphology,
internal architecture, size and shape of cervical lymph nodes. In the head and neck, the
image guidance technique most commonly used has been ultrasound. The real-time capability
and ease of use makes ultrasound the procedure of choice. The evidence of improved efficacy
of ultrasound-guided FNA over palpation-guided FNA in the head and neck also has been well
documented, leading to its acceptance as the standard procedure.
Disadvantages of FNA include a high rate of nondiagnostic samples and incomplete
classification of lymphoma with delayed diagnosis. The core-needle biopsy (CNB) is an
alternative to the established ways of tissue sampling and used very successfully for many
years. As the histologic architecture of the lesion is preserved, it provides a sample that
is adequate for histopathologic and immunohistochemical examination.
To our knowledge, there was only one prospective investigation comparing ultrasound guided
CNB with FNA in the head and neck region. However, the studied population was heterogeneous
and case numbers were limited. The result revealed no significant difference between both
methods. The objective of the present study was to compare ultrasound-guided CNB with FNA in
the assessment of different malignant cervical lymphadenopathies.
Patients and methods
A retrospective study will be performed including consecutive patients over a 3-year period
from 2007 July to 2010 Dec. All patients were seen at our institution with malignant
cervical lymphadenopathies. The biopsies were performed on an outpatient basis, unless the
patient was hospitalized for alternative reasons. Equipment for sonographic studies
consisted of a color Doppler US unit (Philips HDI 5000, Bothell, WA, US) and a 5-12 MHz
broadband linear array transducer.
Morphologic US parameters and vascular features were thoroughly evaluated and recorded on
the PACS system (Marotech Inc, Seoul, South Korea) for the largest nodal lesion in each
patient. Every lymph node was assessed first with gray-scale sonography for morphologic
parameters in horizontal and then longitudinal sections. The short-axis diameter, long-axis
diameter and diameter ratio of short to long axis (S/L ratio) were measured. Echogenicity
with respect to the surrounding soft tissue was assessed and classified as hypoechoic,
isoechoic, or hyperechoic. Lymph node margin was defined as regular or irregular. Echogenic
hilus was distinguished between its presence or absence. Internal echo pattern was divided
into heterogeneity or homogeneity. Vascular patterns were then surveyed by power Doppler
sonography and categorized as the group of avascular or hilar type versus that of mixed,
spotted, or peripheral type.
With the data on history, physical examination, and ultrasound result, we decided that
ultrasound guided needle biopsies would be the first line of investigation for these
lesions. Informed consent for the procedure was obtained from all the patients before
biopsy. In general, FNA was carried out with the array probe guiding the placement of a
22-gauge fine needle within the largest node after sterilization without anesthesia. For
CNB, the skin was sterilized and locally anaesthetized with 2% lidocaine. A modified
non-advancing, disposable, spring-loaded cutting biopsy needle (Temno biopsy system,
Allegiance Healthcare Corporation, McGaw Park, IL, USA) with 15-mm side-notch of 9 cm length
and 18-gauge were used. All biopsies were done by the same experienced otolaryngologist
(Li-Jen Liao) under real-time ultrasound guidance with freehand technique. Three times of
tissue core biopsies were done for each patient. After the biopsy, all patients were asked
to compress the puncture site and were evaluated for possible complications such as bleeding
or bruising for half an hour before leaving the examination room.
The specimens were put in 10% formalin solution for pathologic studies. In the Department of
Pathology, formalin-fixed, paraffin-embeddedm sections from the biopsies were stained with
hematoxylin and eosin for morphologic examination. Further immunohistochemical studies were
performed as necessary.
There are two major study groups according to the treatment status of the patient's
population. The first group included patients who had pathology proofed previous cancer and
with clinically cervical lymphadenopathies after treatment. The second group included
patients with cervical lymphaenopathies but without previous diagnosis of malignancy and
treatment. The disease groups were further classified as metastatic nodes from nonthyroid
primary (META), lymphoma (LYM) and metastatic nodes from papillary carcinoma of the thyroid
(PAP).
The results of cytology and pathology were graded as false negative, suspicious and positive
for malignancy. The final diagnoses of patients were established by the histopathology. The
time of needle biopsy and final diagnosis were traced and recorded.
Statistically, continuous variables were compared by performing the Kruskal-Wallis test.
Category data were compared by using the Chi-square test or Fisher's exact test. The time
from procedure to final diagnosis were expressed in K-M plot and tested with Log-rank test.
All statistical analyses were accomplished using SAS software, version 9.1 (SAS Institute,
Inc, Cary, North Carolina).
Expected Results:
We will know the differential US characteristics in different malignant cervical
lymphadenopathies. Besides, we will know US-FNA or US-CNB is preferred in which situation.
;
Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05640115 -
Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent
|
Early Phase 1 | |
Recruiting |
NCT02891642 -
Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
|
||
Completed |
NCT02282449 -
Power Injectable Versus a Non-Power Injectable, Upper Arm, TIVAD for Chemotherapy
|
N/A | |
Completed |
NCT01199822 -
Study of the Safety and Pharmacokinetics of IMC-3G3 in Japanese Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT01212731 -
Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
|
||
Recruiting |
NCT04122469 -
The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease
|
N/A | |
Recruiting |
NCT03561727 -
Risk Factors for Development of Incisional Hernia in Transverse Incisions
|
N/A | |
Terminated |
NCT03251924 -
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03997968 -
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00092222 -
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
|
Phase 2 | |
Recruiting |
NCT05770102 -
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
|
Phase 2/Phase 3 | |
Recruiting |
NCT05886764 -
Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials
|
N/A | |
Not yet recruiting |
NCT05992363 -
Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction
|
Phase 3 | |
Recruiting |
NCT05761366 -
Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
|
Phase 2 | |
Recruiting |
NCT04887545 -
Immune- and Microenvironment- Proteogenomics Profiling for Classifying Lung Cancer Patients
|
||
Completed |
NCT03061955 -
Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)
|
||
Completed |
NCT03909464 -
Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy
|
||
Active, not recruiting |
NCT02649491 -
Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy
|
N/A | |
Recruiting |
NCT02776995 -
Tumor Monitoring Using Thermography During Radiation Therapy
|
N/A | |
Active, not recruiting |
NCT01242072 -
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
|
Phase 1 |